Iovance Biotherapeutics Surprises with Smaller Loss
Update: 2025-11-06
Description
Iovance Biotherapeutics reported a Q3 loss of $0.25 per share, less than the expected $0.29, but missed revenue estimates. Despite challenges, investors consider potential breakthroughs.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
